Welcome to our dedicated page for Cormedix news (Ticker: CRMD), a resource for investors and traders seeking the latest updates and insights on Cormedix stock.
CorMedix Inc. (Nasdaq: CRMD), also referred to as CorMedix Therapeutics in recent announcements, generates frequent news as a biopharmaceutical company focused on therapeutic products for life-threatening conditions and diseases. Its updates cover commercial performance, clinical development, corporate transactions, and capital markets activity, giving investors and healthcare professionals multiple angles from which to follow the company.
News about CorMedix often highlights the commercial rollout and utilization of DefenCath, an antimicrobial catheter lock solution approved to reduce catheter-related bloodstream infections in certain adult hemodialysis patients using central venous catheters. Press releases have discussed real-world evidence studies with outpatient dialysis organizations, including reductions in infection rates and hospitalizations, as well as recognition such as an Innovative Technology designation from Vizient.
Following its acquisition of Melinta Therapeutics LLC, CorMedix news also covers a broader anti-infective portfolio, including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, along with TOPROL-XL. Investors can expect updates on sales trends, integration progress, and synergy capture related to this transaction. Clinical news includes milestones in the Phase III ReSPECT study of REZZAYO for prophylaxis of invasive fungal disease in allogeneic blood and marrow transplant patients, as well as studies of DefenCath in Total Parenteral Nutrition and pediatric hemodialysis populations.
Regulatory and financial announcements are another important category, such as quarterly and annual results, revenue guidance changes, equity and debt financings, and SEC filings describing material events. Strategic items, including CorMedix’s investment in Talphera and associated board representation and negotiation rights, also appear in the company’s news flow. For investors tracking CRMD, this news page provides a centralized view of earnings releases, clinical data readouts, product designations, conference presentations, and governance updates.
CorMedix (Nasdaq: CRMD) reported Q3 2025 net revenue $104.3M and pro forma net revenue $130.8M, driven by higher-than-expected outpatient DefenCath utilization and partial-quarter Melinta sales. The company posted Q3 net income $108.6M and adjusted EBITDA $71.9M, with basic and diluted EPS of $1.42 and $1.26. Management raised FY 2025 pro forma net revenue guidance to $390–$410M and fourth-quarter revenue guidance to $115–$135M, and increased fully synergized pro forma adjusted EBITDA guidance to $220–$240M. The Melinta acquisition closed August 29, 2025; estimated 2025 synergy capture is ~$30M of an expected $35–$45M annual run rate. Cash and short-term investments were $55.7M at Sept. 30, 2025, with projected year-end cash ~$100M. ReSPECT Phase III enrollment completed; top-line data expected in 2Q 2026.
CorMedix (Nasdaq: CRMD) will report third-quarter 2025 financial results for the period ended September 30, 2025, before the market opens on November 12, 2025, and will host a corporate update conference call at 8:30 AM ET that day.
The company is commercializing DefenCath for prevention of catheter-related bloodstream infections in adult hemodialysis patients and, following its August 2025 acquisition of Melinta Therapeutics, is commercializing a portfolio of anti-infective products (including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA) and TOPROL-XL.
CorMedix has ongoing DefenCath studies in total parenteral nutrition and pediatric populations, and REZZAYO has an ongoing Phase III prophylaxis study with topline results expected in Q2 2026.
CorMedix (Nasdaq: CRMD) announced that DefenCath, its FDA‑approved antimicrobial catheter lock solution, received an Innovative Technology designation from Vizient on Oct. 23, 2025.
DefenCath is approved for a limited population of adult patients on chronic hemodialysis via central venous catheter and in a Phase 3 LOCK IT-100 study showed a 71% reduction in risk of catheter-related bloodstream infections with adverse events comparable to control. CorMedix is conducting a real‑world evidence study in >2,000 patients and expects interim data around year-end. Vizient represents approximately $156 billion in annual purchasing volume.
Talphera (Nasdaq: TLPH) appointed Joe Todisco, CEO of CorMedix (Nasdaq: CRMD), to its Board of Directors effective Oct 21, 2025.
CorMedix made a strategic investment in Talphera in Sept 2025 and, under that transaction, gained the right to nominate a board representative and a 60-day exclusive negotiation period triggered by the announcement of primary endpoint and topline results from the NEPHRO CRRT clinical study. Talphera and CorMedix cite potential regulatory progress for Niyad with management referencing a possible approval in 2026.
CorMedix (Nasdaq: CRMD) reported preliminary unaudited Q3 2025 results and raised 2025 pro forma net revenue guidance. Key figures include Q3 pro forma net revenue >$125M, DefenCath Q3 net revenue >$85M, and Q3 unaudited company net revenue >$100M. Management raised full‑year 2025 pro forma net revenue guidance to at least $375M and expects Q3 adjusted EBITDA ≥ $70M.
The company forecasts at least $30M of go‑forward operating synergies before year‑end 2025 from the Melinta integration, with an additional $5–$15M targeted in 2026. Cash and short‑term investments were approximately $56M on Sept 30, 2025, with a projected year‑end cash balance of ~$100M. Clinical update: Phase III ReSPECT enrollment complete; data expected 2Q 2026.
CorMedix (NASDAQ: CRMD) has announced the completion of enrollment in its Phase III ReSPECT clinical trial for REZZAYO® (rezafungin). The study evaluates REZZAYO as a prophylactic treatment against Candida, Aspergillus, and Pneumocystis infections in patients undergoing allogeneic blood and marrow transplantation.
The trial, sponsored by Mundipharma, compares once-weekly REZZAYO to standard antimicrobial treatment. The dosing regimen includes a 400 mg loading dose followed by 200 mg weekly for 13 weeks. Topline results are expected in Q2 2026. The study's primary endpoint is fungal-free survival at day 90, with secondary endpoints including IFD incidence, toxicity-related discontinuation, and mortality.
CorMedix (NASDAQ:CRMD) has announced a strategic $5 million minority investment in Talphera (NASDAQ:TLPH), acquiring 9,090,909 shares at $0.55 per share. The investment is part of Talphera's private placement financing to fund its Phase 3 study of Niyad™, a breakthrough-designated anticoagulant for extracorporeal circuits.
As part of the deal, CorMedix receives exclusive first negotiation rights for a potential Talphera acquisition, with a 60-day exclusive period following Phase 3 results. Additionally, CorMedix gains the right to nominate one director to Talphera's board. Niyad targets an estimated 165,000 acute kidney injury patients annually who receive CRRT treatment and cannot tolerate heparin.
Talphera (NASDAQ:TLPH) has secured a private placement financing of up to $29 million led by CorMedix Inc. as the strategic investor, along with institutional investors including Nantahala Capital, Rosalind Advisors, and Rock Springs Capital. The financing includes $17 million in the first closing (expected September 10, 2025) and potential $12 million in a second tranche upon achieving the primary endpoint in the NEPHRO CRRT study.
The first closing involves issuing 25,036,363 shares at $0.55 per share and 5,845,455 pre-funded warrants at $0.549. CorMedix receives a 60-day exclusivity period to negotiate Talphera's acquisition following NEPHRO study results and gains board nomination rights. The funding is expected to support Talphera through the planned Niyad PMA approval in H2 2026.
CorMedix (NASDAQ:CRMD) has completed its acquisition of Melinta Therapeutics in a transformational deal valued at $300 million, comprising $260 million in cash and $40 million in equity. The acquisition brings seven marketed products to CorMedix's portfolio and is expected to generate significant financial benefits.
The company has raised its financial guidance, projecting pro forma 2025 combined revenues of $325-350 million and pro forma synergized adjusted EBITDA of $165-185 million. The transaction is expected to achieve annual run-rate synergies of $35-45 million and be accretive to EPS with double-digit accretion in 2026.
The deal includes potential additional payments of up to $25 million tied to regulatory milestones for REZZAYO™'s expanded indication, which could generate peak annual sales exceeding $200 million if approved.
CorMedix (NASDAQ:CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening conditions, announced its participation in two major healthcare investor conferences in September 2025.
The company's senior management will present at the Cantor Global Healthcare Conference on September 5 at 8:35am ET and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10 at 10:45am ET. Both presentations will be in a fireside chat format with webcasts available.